![OKYO Pharma Announces Distinguished Ophthalmologists with Expertise in the Medical and Surgical Treatment of Ocular Surface Diseases Join its Scientific Advisory Board](https://okyopharma.com/wp-content/uploads/2023/07/cropped-favi-1.png)
![OKYO Pharma Announces Distinguished Ophthalmologists with Expertise in the Medical and Surgical Treatment of Ocular Surface Diseases Join its Scientific Advisory Board](https://okyopharma.com/wp-content/uploads/2023/07/cropped-favi-1.png)
Recent Posts
- OKYO Pharma to Initiate Neuropathic Corneal Pain Trial for OK-101
- OKYO Pharma Announces Promising Categorical Data from OK-101 Phase 2 Trial in Dry Eye Disease
- OKYO Pharma Announces Participation in May 2024 Investor Conferences
- OKYO Pharma Announces Upcoming Presentation of OK-101 Phase 2 Data for Dry Eye Disease at the Dry Horizons Symposium, a Partner Meeting of the Association for Research in Vision and Ophthalmology (ARVO)
- OKYO Pharma to Reschedule Key Opinion Leader Event in Dry Eye Disease to May 2024
Recent Comments
No comments to show.